Open AccessAntitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts
Author(s) -
Hamaguchi Tetsuya,
Matsumura Yasuhiro,
Nakanishi Yukihiro,
Muro Kei,
Yamada Yasuhide,
Shimada Yasuhiro,
Shirao Kuniaki,
Niki Hisae,
Hosokawa Saiko,
Tagawa Toshiaki,
Kakizoe Tadao
Publication year - 2004
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2004.tb02495.x
Subject(s) - monoclonal antibody , doxorubicin , cancer , colorectal cancer , cancer research , liposome , medicine , antibody , chemistry , chemotherapy , immunology , biochemistry
MCC‐465 is an immunoliposome‐encapsulated doxorubicin. The liposome is tagged with polyethylene glycol and the F(ab) 2 of a monoclonal antibody named GAH, a human antibody obtained by the hybridoma technique. The epitope recognized by GAH is not well characterized, but human gastric, colorectal, and mammary cancer cells were GAH‐positive, while the normal counterparts were GAH‐negative. Pegylated liposome doxorubicin (PLD) and MCC‐465 did not show significant antitumor activity against GAH‐negative Caco‐2 xenografts. On the other hand, MCC‐465 exhibited significantly superior antitumor effects against GAH‐positive WiDr‐Tc and SW837 xenografts, compared with PLD. Immunohis‐tochemistry with GAH revealed that 94% (100 of 106) of surgical specimens of colorectal cancer were GAH‐positive. These results warrant a phase I clinical trial of MCC‐465 for patients with metastatic colorectal cancer.